NCT04717414: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
- State
- Under way
- Phase
- Phase 3
- People
- 313 taking part
- Started
- 25 Feb 2021
- Primary completion
- 26 May 2025
- Arms
- Experimental Arm: Luspatercept (ACE-536)
- Results
- Posted on the registry
- 22 Jan 2021: Trial registered
- 25 Feb 2021: Trial started
- 16 Jul 2026: Trial results posted